INFLUENCE OF MILDRONATE ON EFFICIENCY OF ANTIANGINAL THERAPY IN PATIENTS WITH STABLE BURDEN ANGINA
Aim. To study influence of mildronate (M) on treatment efficiency of patients with ischemic heart disease (IHD), receiving standard antianginal therapy (AAT)Materials and methods. Double-blind, randomized, placebo-controlled study was carried out in parallel groups. All patients continued the earlie...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-12-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/352 |
| Summary: | Aim. To study influence of mildronate (M) on treatment efficiency of patients with ischemic heart disease (IHD), receiving standard antianginal therapy (AAT)Materials and methods. Double-blind, randomized, placebo-controlled study was carried out in parallel groups. All patients continued the earlier prescribed AAT without changes. After control period (10-14 days) was over, randomization of patients either to the treatment group (M 500mg twice per day), or to the control group (placebo (Pl) twice per day) was made for 6 weeks therapy. Criterion of treatment efficiency: increase in duration of trial with burden on treadmill (TB), decrease in angina attack frequency (AA) and reduction in nitroglycerin taking (NTT). TB was carried out at the beginning (TB-1), at the end of the control period (TB-2), and at the end of the treatment (TB-3).Results. TB-1 and TB-2 had good reproducibility, their duration didn’t differ. At the end of the treatment additionally with M, growth in duration of TB-3 (p=0,002) was registered, while there was no growth of TB duration with the Pl treatment (p=0,07). During the treatment decrease in AA number both with M (p=0,002), and with Pl (p=0,02) was noted. With M treatment decrease in NTT treatment (p=0.02) was observed, while NTT with Pl didn’t change (p=0,7). Number of side effects, registered with M and Pl, didn’t differ.Conclusion. Mildronate provides additional benefits for patients with IHD with stable burden angina, when they do not reach desired effect with the prescribed AAT. |
|---|---|
| ISSN: | 1819-6446 2225-3653 |